The following products and technologies are currently open for partnership evaluation with a strategic partner:
Vyome’s MRTTM approach focuses on the development of effective, targeted and safe topical therapeutics against fungal and bacterial infections of the skin, with better pharmacological profiles than the incumbent therapies. This promising MRTTM intends to reduce dosages and application frequencies of topical formulations, achieve faster onset of action and amplify relief for the patient.
Currently, Vyome is open for various partnership opportunities for the Molecular Replacement Therapy Platform technology, and for its clinically tested products. For more details, please write to us: firstname.lastname@example.org / email@example.com
Vyome has developed a novel and breakthrough Scalp Care Leave-On Product VB 001 for treating Seborrheic Dermatitis and Dandruff, using innovative Molecular Replacement Therapy (MRTTM). VB 001 is a unique, clinically tested IP based product in a novel delivery format. VB 001 provides significantly better results in treating the global unmet need of sustained cure of Dandruff.
VB 001 is available for various partnership models globally and in various regions.
Vyome has developed a novel and breakthrough Anti Dandruff Wash-Off Shampoo Product VB 3222, using innovative Molecular Replacement Therapy (MRTTM). VB 3222 is a clinically proven IP based shampoo which provides significantly better results than the currently available ordinary anti-dandruff shampoos in reducing the flaking and itching. It also significantly improves the hair sensorial parameters like softness, reduction in detanglement etc.
VB 3222 is available for various partnership models globally and in various regions.
Vyome is also targeting multiple fungal indications of skin, through its innovative prescription product VB 7731, which is a Ketoconazole Emulsion Gel. The gel has been developed using innovative MRTTM Technology, which significantly enhances the efficacy of Ketoconazole.
VB 7731 is currently in pre-clinical testing phase and is available for further development and licensing.
In addition to the products listed above, MRTTM technology platform can also be used for co-development for different fungal actives and fungal indications.
For more details, please write to us: firstname.lastname@example.org / email@example.com
Copyright © 2015 Vyome Biosciences. All rights reserved.